Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones

Table 5

In vivo efficacy log10 CFU reduction in bacterial load in lungs and spleen.

Test group	Organ	Dose mg/Kg/dy	Mean ± SEM CFU	Log10CFU reduction	Activity
Untreated d13	Lung	n/a	6.90 ± 0.11	n/a	n/a
	Spleen		4.75 ± 0.21
Untreated d22	Lung	n/a	8.06 ± 0.11	n/a	n/a
	Spleen		6.38 ± 0.07
INH	Lung	25	4.77 ± 0.12	3.29	Active
	Spleen		2.04 ± 0.38	4.34	Active
2l (306019)	Lung	150	7.67 ± 0.22	0.39	Inactive^a
	Spleen		6.24 ± 0.06	0.14	Inactive^a
1g (306027)	Lung	300	7.28 ± 0.14	0.78	Slightly active
	Spleen		5.95 ± 0.09	0.43	Inactive^a
PH-27 (306006)	Lung	150	6.62 ± 0.08	1.44	Active
	Spleen		4.64 ± 0.21	1.74	Active

^a306027: slightly active in lung, but activity in spleen was not statistically significant.